BioStrand, a subsidiary of ImmunoPrecise Antibodies (IPA), operates at the intersection of biotech, life science, (bio)informatics, and AI. Our unique capabilities allow us to analyze large data sets with remarkable accuracy, providing groundbreaking insights in therapeutic and diagnostic research. Our patented HYFT technology and LENSᵃⁱ software make it possible to apply these capabilities across numerous life science disciplines. We are deeply committed to developing a next-generation end-to-end omics drug development platform that harnesses our advanced tools to accelerate discoveries.